Tatsuya Ishii

Tatsuya Ishii

Auto-generated profile, based on publicly available information

Tatsuya Ishii

University of the Ryukyus Hospital, Okinawa Prefecture, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2025 in Regenerative Therapy
Verified
Journal Article
Open access
YSYusuke Shimizu
Yusuke Shimizu
YIYoshikazu Inoue
Yoshikazu Inoue
NMNaoki Matsuura
Naoki Matsuura
TITatsuya Ishii
Tatsuya Ishii
YSYoshihiro Sowa
Yoshihiro Sowa
ENEdward Hosea Ntege
Edward Hosea Ntege
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics that recapitulate key paracrine functions of MSCs whilst mitigating limitations of viable-cell therapies. Clinical translation is hindered by inconsistent dose metrics, lack of validated potency assays, and manufacturing complexities. Here we review advances in MSC-EV standardisation, source and culture determinants, engineering and delivery platforms, and clinical applications, exemplified by chronic wound healing. We operationalise dual-metric dosing (particles plus protein) linked to mechanism-aligned potency assays, adopt a route-aware exposure–response framework to guide delivery strategies, and propose decision matrices aligning MSC sources and bioprocesses with indication-specific tasks. Good Laboratory Practice safety panels and Good Manufacturing Practice scale-up strategies are outlined to support regulatory readiness. Early clinical studies demonstrate feasibility and short-term safety but reveal heterogeneous efficacy, underscoring the need for harmonised dosing and potency measures. Collectively, these insights provide a roadmap to advance MSC-EVs as indication-matched regenerative medicines.

22 October 2026 in Archives of Plastic Surgery
Verified
Journal Article
Open access
TITatsuya Ishii
Tatsuya Ishii
YSYusuke Shimizu
Yusuke Shimizu
YCYasutsugu Chinen
Yasutsugu Chinen
NMNaoki Matsuura
Naoki Matsuura
TNTaiki Nagatsuka
Taiki Nagatsuka
RAReiko Asato
Reiko Asato
Pectus excavatum is a characteristic thoracic deformity of Marfan syndrome (MFS) that plastic surgeons often encounter during initial evaluation. Herein, we have described the case of a 2-year-old boy who presented with pectus excavatum. However, the initial assessment did not adequately explore the physical features or family history suggestive of MFS. At the 3-year health checkup, the patient was observed to have long fingers, leading to a referral to pediatrics. Genetic testing revealed that the patient, his sister, and father had a fibrillin-1 (FBN1) mutation. Multidisciplinary management was initiated for the children, and early detection of asymptomatic dilation of the sinus of Valsalva in the father led to preventive aortic root replacement (remodeling procedure). This case illustrates that plastic surgery can serve as an entry point for MFS detection, and insufficient evaluation risks missing life-threatening complications.

25 September 2026 in JPRAS Open
Verified
Journal Article
Open access
TITatsuya Ishii
Tatsuya Ishii
YSYusuke Shimizu
Yusuke Shimizu
ENEdward Hosea Ntege
Edward Hosea Ntege
RAReiko Asato
Reiko Asato
NMNaoki Matsuura
Naoki Matsuura
Long-standing blepharoptosis following trauma remains incompletely characterised. We report a 57-year-old man with unilateral blepharoptosis of 40 years' duration, with patient-reported immediate onset after blunt periorbital trauma and more recent worsening. The temporal association supports a traumatic contribution, although superimposed involutional aponeurotic change cannot be excluded. Preoperative margin reflex distance 1 (MRD1) and clinical levator function (LF; upper-eyelid excursion) of the affected eyelid were -0.5 mm and 2.0 mm, respectively. Intraoperatively, broad detachment of the levator aponeurosis was identified. After adhesiolysis and lateral horn release, attempted upgaze elicited visible posterior retraction and transmitted tension within the exposed levator-aponeurosis complex; these qualitative findings supported the decision to perform external levator aponeurosis advancement. At 3 years, MRD1 and LF were 2.7 mm and 12.0 mm, respectively. In this patient, very low preoperative clinical LF did not preclude durable improvement in upper-eyelid excursion after release of restriction and levator aponeurosis advancement.

29 July 2026 in Regenerative Therapy
Verified
Journal Article
Open access
YSYusuke Shimizu
Yusuke Shimizu
ENEdward Hosea Ntege
Edward Hosea Ntege
NMNaoki Matsuura
Naoki Matsuura
TITatsuya Ishii
Tatsuya Ishii
HSHiroshi Sunami
Hiroshi Sunami
YIYoshikazu Inoue
Yoshikazu Inoue